BRAF and non-small cell lung carcinoma: Initial studies demonstrated the clinical activity of selective inhibitors dabrafenib or vemurafenib as single agents in previously treated patients with BRAFV600E-mutant NSCLC, observed in 50% of patients with a BRAF mutation [5, 6].